

Tumor Immunology and Immunotherapy

Edited by

Robert C. Rees

Director and Professor of Tumor Biology

The John van Geest Cancer Research Centre

Nottingham Trent University

Nottingham, UK

OXFORD
UNIVERSITY PRESS

Contents

Abbreviations *xvii*

Contributor List *xxi*

- 1** Adaptive T-cell immunity and tumor antigen recognition *1*
Pedro Romero and Pierre G Coulie
- 2** Impact of ageing and body mass on cancer immunotherapy outcomes *15*
*Gail D Sckisel, Arta M Monjazebl, Annie Mirsoian, Anthony E Zamora,
Steven Grossenbacher, and William J Murphy*
- 3** The potential of natural killer cells in cancer immunotherapy *31*
Thomas CC Tan, Jean-Marc Doisne, and Francesco Colucci
- 4** The tumor microenvironment: The role of tumor-associated macrophages
in cancer progression and responses to therapy *43*
Russell Hughes and Munitta Muthana
- 5** ‘Hard’ and ‘soft’ loss of MHC class I expression in cancer cells *63*
Natalia Aptsiauri, Angel M. Garcia-Lora, and Federico Garrido
- 6** Modulation of the adaptive immune system through chronic inflammation
and T-regulatory responses *79*
Angus G Dalgleish
- 7** Myeloid-derived suppressor cells: Immune-suppressive cells
that facilitate tumor progression and promote and deter cancer-associated
inflammation *95*
*Pratima Sinha, Virginia Clements, Meghan Burke, Catherine Fenselau,
and Suzanne Ostrand-Rosenberg*
- 8** Triggering death receptors to promote cancer cell death *113*
Thomas J Sayers and Neil A Cross
- 9** Identification of tumor antigens for clinical evaluation *127*
*Jayakumar Vadakekolathu, Amanda K Miles, David J Boocock,
and Stephanie EB McArdle*
- 10** Viral antigens as targets for prophylactic and therapeutic intervention
in cancer *141*
Peter L Stern and Kenneth Oguejiofor
- 11** HER2/neu as a target for vaccine and antibody-directed therapies *155*
Constantin N Baxevanis and Sonia A Perez
- 12** Pre-clinical evaluation of immunotherapy: The case for prostate cancer
and the TRAMP model *173*
Matteo Bellone, Sara Martina Parigi, and Elena Jachetti

- 13** Tumor-associated antigens characterized in a conceptual framework of biology, microenvironment, and therapy 189
Per thor Straten, David Schrama, Jürgen C Becker, and Mads Hald Andersen
- 14** Predictive biomarkers to better select patients for cancer immunotherapy 203
Marius Strioga and Eric Tartour
- 15** Viral platforms for expression of tumor antigens in cancer immunotherapy 217
Karishma Rajani, Vanesa Alonso-Camino, Nicolas Boisgerault, and Richard Vile
- 16** Translating research into clinical practice: lessons from the immunology and immunotherapy of haemopoietic malignancies 235
Paul Moss
- 17** DNA vaccines 251
Lindy G Durrant, Wei Xue, Lee R Machado, Rachael L Metherringham, and Victoria A Brentville
- 18** Programming the immune system through childhood infections: MUC1 tumor-associated antigen (TAA) as a disease-associated antigen (DAA) 265
Uzoma K Iheagwara, Pamela L Beatty, Bianca Su-Wan Chan, Lora H Rigatti, Ted Ross, and Olivera J Finn
- 19** Vaccination against myeloid leukaemias using newly defined antigens 281
Susanne Hofmann, Ghazala Khan, Viktoriya Boncheva, Jochen Greiner, and Barbara-ann Guinn
- 20** Immune-checkpoint blockade in cancer immunotherapy 295
Patrick A Ott and F Stephen Hodi
- 21** Multi-peptide cancer vaccines for clinical application 309
Harpreet Singh-Jasuja, Toni Weinschenk, and Steffen Walter
- 22** Adoptive T-cell therapy using TILs for the treatment of metastatic melanoma 327
Marco Donia, Eva Ellebæk, and Inge Marie Svane
- 23** Chimeric antigen receptor gene therapy in cancer 343
John S Bridgeman and David E Gilham
- 24** The vaccinal effect of monoclonal antibodies in cancer therapy 357
Claire Deligne, Sophie Sibénil, and Jean-Luc Teillaud
- 25** Antibody therapies: defining appropriate cell surface epitopes for targeting tumors 373
Gabriele Multhoff and Michael Stanglmaier
- 26** Adoptive lymphocyte (stem cell) therapy in cancer 387
Sophie Derniame and Aurore Saudemont

- 27** Cancer stem cells (CSCs) and epithelial-to-mesenchymal transition (EMT):
Tumor cell plasticity challenges immunotherapy 401
Tarik Regad and Morgan G Mathieu
- 28** Immune escape and ageing of the immune system compromises the immune
response to tumor antigens 415
Ludmila Müller and Graham Pawelec
- Index 433